FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022

Copenhagen, Denmark, 10 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has selected lung cancer as the second clinical indication for FG001.The clinical trial will be conducted at Rigshospitalet in Denmark during 2022.

The release as fetched from its publisher. fluoguide.com ↗